About
We’re making a better future of the humanity
and science technology through ongoing research.
No.1 player
No.1 player in South Korea with over 70%
market share in allergy diagnostics
First
South Korea’s first
MP-CLIA technology INF-γ assay
Our products
We specialize in diagnostic reagents for allergies, tuberculosis, and respiratory diseases.
Allergy
AdvanSure™ AlloScreen Max108 Panel
Allergy screening product that can test 108 types of allergen at once
ViewLatent TB
AdvanSure™ i3 TB-IGRA
Optimized solution for latent tuberculosis test in general hospitals
ViewRespiratory Virus
AdvanSure™ RV-Plus real-time RT-PCR
Reagent for 15 types of respiratory
viruses test
TB/NTM
AdvanSure™ TB/NTM real-time PCR
Reagent for M. tuberculosis complex/
Nontuberculosis mycobacteria test
Nucleic Acid Extraction
AdvanSure™ E3 System
Automated nucleic acid extractor which can extract 48 samples within 15~35 minutes
ViewESG MANAGEMENT
We are practicing ESG activities
for a sustainable future.
CAREERS
We are looking for new talents!
INnovative
The ability to propose and create innovative and creative ideas.
VIsionary
The ability to foresee the future with a vision and take proactive steps.
TRailblazer
The ability to trailblaze new paths and drive innovative changes.
Open-minded
Synthesizer
Open-minded synthesizer who embraces and harmonizes diverse ideas.
News Room
Our latest news
Moving forward, Invitros will continue to strengthen its ESG performance through transparent and responsible management practices.
Founded in France in 2007, EcoVadis has assessed the sustainability performance of over 150,000 companies across 185 countries.
Over 1,400 global corporations rely on EcoVadis to evaluate the ESG performance of their supply chains and partners.
EcoVadis is widely recognized as a highly trusted organization that objectively evaluates corporate sustainability by thoroughly reviewing all evidence submitted for each detailed item in the four assessment areas.
In 2008, LG Chem released the “AdvanSure™ AlloScreen reagent,” a multi-drug substance-testing product, for the first time in Korea, through research and development on the diagnosis of allergies with Yonsei University Medical School.
The products launched this year added house dust mites, pollen allergies, and substances unique to Koreans through continuous research.
In particular, this reagent expands from 62 existing elements, enabling 93 kinds of materials to be inspected simultaneously with a drop of blood in three hours, saving time and cost of inspection, as well as providing food and the respiratory origin, while identifying the cause of the substance.
Allergies are types of autoimmune diseases that cause hypersensitivity reactions to external substances. It causes allergic asthma, eczema, and rhinitis, with symptoms such as a runny nose, and itchiness that distributes to many patients throughout the world.
Methods for treating allergies include the use of antihistamines, steroids, and immunotherapy, the most efficient and easiest way.
The domestic market is estimated to be about 25 billion won ($21 million), with the number of patients increasing every year due to the effects of fine dust and environmental hormones. Allergies caused by two or more causes are also increasing, making it necessary to know what causes allergens before they appear, the company said. (2017.08.10)
[Link: https://www.koreabiomed.com/news/articleView.html?idxno=1055]